MedPage Today July 1, 2024
Natalie Muth, MD, MPH, MBA, RDN

— Prepare patients early for a time when medication is no longer an option

At the November 2022 Obesity Week in San Diego, it was clear something big was happening. A late-breaking session released results of the STEP TEENS phase IIIa trial, showing 16% weight loss in adolescents with obesity treated with once-weekly semaglutide (Wegovy) for 68 weeks. The side effects were manageable and similar to those experienced in adults — nausea, vomiting, constipation.

A month later, semaglutide received FDA approval for weight management in adolescents ages 12 and older. And just a month after that, the American Academy of Pediatrics (AAP) released the first-ever clinical practice guidelines for the treatment of children and adolescents with obesity, including pharmacological options...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Primary care, Provider, Trends
Related Articles:
Employers Reap $190 for Every $100 Invested in Behavioral Health
Calling patients at their home
Obesity Management: Researchers Develop New Tool to Measure Food Noise
Preserving access, affordability are Americans’ top healthcare priorities: Gallup
The boomer-driven ASC boom

Share This Article